Market Overview

UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Dropout Assumptions

Share:
Related AEGR
Mid-Morning Market Update: Markets Drop; Verizon Profit Tops Estimates
Benzinga's Top Upgrades

In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised the price target from $41.00 to $52.00.

In the report, Karnauskas noted, “AEGR has made assumptions for dropouts, which are key to their guidance of ending the year with 250-300 patients on Juxtapid. While our analysis suggests the co is well on track to beat the guidance, Aegerion wants to be conservative and get more data on dropouts ahead of modifying guidance. Dropout color might come later in the year when the co has more data (too soon for 1Q13 call). While the ph 3 saw 20% drop outs, AEGR expects much lower.”

Aegerion Pharmaceuticals closed on Wednesday at $38.49.

Latest Ratings for AEGR

DateFirmActionFromTo
Feb 2016Bank of AmericaDowngradesNeutralUnderperform
Dec 2015Guggenheim SecuritiesUpgradesSellBuy
Nov 2015Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (AEGR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters